| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 99, 13-42, Copyright © 1980 by American Society for Investigative Pathology
REGULAR ARTICLES |
JF Van Vleet, VJ Ferrans and WE Weirich
Chronic adriamycin (ADR) intoxication was produced in three groups of beagle dogs by weekly intravenous injections (1 mg/kg body weight) for 20 weeks (cumulative dose 400 mg/sq m). Group A (6 dogs) received ADR only; Group B (6 dogs) were given ADR and weekly doses of vitamin E (17 mg/kg body weight) as alpha-tocopherol acetate; and Group C (6 dogs) received ADR and weekly doses of vitamin E as did Group B and selenium (0.06 mg/kg body weight as selenite). Each of the 18 dogs developed ADR- induced cardiomyopathy (CMY), and death occurred in 11 dogs during Weeks 17-20. Mortality was lowest in Group B (2 of 6), but no differences between groups were seen either in survival time of the dogs that died or in severity of CMY. Cardiomyopathy was more severe in dogs that died than in survivors. Congestive heart failure with transudation was present in 4 of 11 dogs that died. Cardiac histopathology was characterized by vacuolar degeneration of myocytes. Myocardial damage was most severe in the left ventricle and the ventricular septum, intermediate in the right ventricle and the left atrium, and least in the right atrium. Ultrastructural study showed that an early alteration in damaged myocytes was distention of sarcoplasmic reticulum to form sarcoplasmic vacuoles. Occasional damaged fibers had myofibrillar lysis and focal proliferation of sarcoplasmic reticulum. This study demonstrates that the dog offers a suitable model for studies of chronic ADR cardiotoxicity in man. The lack of cardioprotection from vitamin E and selenium supplementation fails to support the proposed role of lipoperoxidative damage in the development of chronic ADR-induced CMY.
This article has been cited by other articles:
![]() |
K. A. Conklin Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity Integr Cancer Ther, June 1, 2005; 4(2): 110 - 130. [Abstract] [PDF] |
||||
![]() |
F. A. A. van Acker, S. A. B. E. van Acker, K. Kramer, G. R. M. M. Haenen, A. Bast, and W. J. F. van der Vijgh 7-Monohydroxyethylrutoside Protects against Chronic Doxorubicin-induced Cardiotoxicity When Administered Only Once Per Week Clin. Cancer Res., April 1, 2000; 6(4): 1337 - 1341. [Abstract] [Full Text] |
||||
![]() |
G.-W. Wang and Y. J. Kang Inhibition of Doxorubicin Toxicity in Cultured Neonatal Mouse Cardiomyocytes with Elevated Metallothionein Levels J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 938 - 944. [Abstract] [Full Text] |
||||
![]() |
G. MINOTTI, G. CAIRO, and E. MONTI Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J, February 1, 1999; 13(2): 199 - 212. [Abstract] [Full Text] |
||||
![]() |
P Venditti, M Balestrieri, T De Leo, and S Di Meo Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres Cardiovasc Res, June 1, 1998; 38(3): 695 - 702. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |